This is an aggregated industry headline. Read the full story at FierceBiotech →
Sanofi's R&D chief Ashrafian to hit the exit as new CEO seeks to fix stuttering pipeline with Roche alum
Recently appointed Sanofi CEO Belén Garijo has stamped her mark on the organization, hiring Paulo Fontoura, M.D., Ph.D., to replace Houman Ashrafian, Ph.D., as the head of the company's stuttering R&D group.
By FierceBiotech
· Jun 22, 2026
· via FierceBiotech
Image: FierceBiotech
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Pharma companies have been part of the global economy and health systems for centuries. Now, as drugmakers pla…
The WeekBriefing
The move follows a June 8 deadline set for hospitals that failed to provide claims data required under Lilly’s…
The WeekBioPharma Dive ↗
Women's health audiences have long memories and finely tuned instincts for what is performative.…